Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 29Multiple Myeloma 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Lymphoma 20Melanoma 16Lymphoma, Non-Hodgkin 14Colorectal Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Wilms Tumor 11Myelodysplastic Syndromes 10Lung Neoplasms 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Colonic Neoplasms 8Sarcoma, Ewing 7Osteosarcoma 7

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × 30 days × Clear all
NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Dana-Farber Cancer Institute

Phase 2 Completed
82 enrolled 20 charts
Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡